Drug Database
HY

hyaluronidase (Amphadase)

✓ Approved

Amphastar Pharmaceuticals, Inc. · HYAL1

什么是 hyaluronidase?

hyaluronidase 是一种治疗药物,由Amphastar Pharmaceuticals, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Amphadase
公司Amphastar Pharmaceuticals, Inc.
分子靶点HYAL1
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

hyaluronidase 作用于 1 个分子靶点:

HYAL1hyaluronidase 1 (LUCA1, MPS9)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

hyaluronidase 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresAdjuvant therapy✓ Approved

相关研究文献

PubMedBulletin of experimental biology and medicine2026-11-18

Anti-Inflammatory and Antifibrotic Effects of Hyaluronidase Versus a Phosphodiesterase Type 4 Inhibitor in C57BL/6 Mice with Emphysema.

Ermakova N N NN, Pan E S ES, Zhukova M A MA, Pan V Y VY et al.

Using a model of pulmonary emphysema induced by LPS and cigarette smoke extract, the effects of hyaluronidase (HYAL) were compared with those of the phosphodiesterase type 4 (PDE4) inhibitor roflumilast. Roflumilast (5 mg/kg) reduced inflammation and collagen deposition in peribronchial zones without affecting emphysematous changes. HYAL at a dose of 16 IU/mouse increased inflammatory infiltration in the upper and lower lung regions, leading to the degradation of perivascular and peribronchial collagen and elastin in the middle and lower lung regions and exacerbating emphysema and vascular hyperemia. HYAL at a dose of 8 IU/mouse reduced inflammation in the lungs, limited fibrotic remodeling of the parenchyma, bronchi, and vessels by reducing the area of elastin and collagen fibers, and prevented the destruction of interalveolar septa. Thus, the administration of HYAL in low doses is a promising strategy for combating peribronchial and perivascular deposition of fibrotic masses in pulmonary emphysema. These results may serve as a basis for developing therapies against fibrosis in patients with chronic obstructive pulmonary disease and pulmonary emphysema.

PMID 43045897
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Delayed Inflammatory Reactions to Hyaluronic Acid Fillers in a Patient Undergoing Dupilumab Therapy: A Case Report.

Alkhuzaim Osamah O, Almeziny Abdullah A

Delayed inflammatory reactions to hyaluronic acid (HA) dermal fillers are uncommon but clinically significant, particularly in patients receiving immunomodulatory biologic therapies. Dupilumab, an interleukin-4 receptor alpha (IL-4Rα) inhibitor approved for chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 inflammatory conditions, has not been previously associated with this adverse event. To report a case of delayed inflammatory filler reactions at previously injected hyaluronic acid filler sites associated with dupilumab administration, and to discuss proposed immunological mechanisms, differential diagnoses, and management considerations. A 34-year-old female with refractory CRSwNP, who had previously tolerated HA skinbooster injections without complications, developed facial warmth, pain, and hyperpigmented swelling at prior filler sites within 1 h of receiving her first dupilumab 600 mg dose. Within 24 h symptoms progressed to persistent bilateral cheek nodules. Similar, although to a lesser extent, reactions were observed after some of the later doses of dupilumab and treatment with hyaluronidase resulted in partial resolution. Reactions reappeared with additional dosing of dupilumab, requiring further doses of hyaluronidase to mitigate these reactions. Score on the Naranjo Adverse Drug Reaction Probability Scale: 8 (probable but not confirmed temporal correlation between dupilumab and inflammatory filler reaction). One possible mechanistic explanation is that dupilumab-mediated IL-4/IL-13 inhibition may shift ambient filler sites toward Th1/Th17-dominant immune activity; this hypothesis remains speculative without histopathological confirmation. Alternative diagnoses including infection, biofilm formation, and idiopathic granulomatous inflammation cannot be excluded. To our knowledge the first case report of delayed inflammatory filler reactions associated with biologic therapy. This potential interaction is important since it may expose patients who are on biologics to increased susceptibility to complications following esthetic procedures, and thus clinicians performing these esthetic treatments in these patients should be aware of this risk. This is constrained by the lack of imaging and biopsy investigation. More studies are necessary for understanding the mechanisms of this association and improving management strategies.

PMID 43047166
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Management of Polycaprolactone Filler-Induced Ischemia With "THIS and FAT" Protocol: A Case Series.

Nazari Shahriar S, Pourani Mohammad Reza MR, Bayatparidary Foroohe F, Sadeghi Mohammad Saleh MS et al.

Polycaprolactone (PCL)-based fillers demonstrate clinical advantages and favorable aesthetic outcomes. However, due to the nature of their constituents, they present unique and serious challenges, particularly regarding vascular adverse events such as embolism, tissue necrosis, and visual loss. This study presents a case series of five patients with PCL filler-induced vascular complications treated using the "THIS and FAT" protocol. This protocol includes botulinum toxin, high-dose hyaluronidase, injectable platelet-rich fibrin (iPRF), solid platelet-rich fibrin (sPRF), antibiotics and adjunctive medications, nanofat injection, debridement, and nanofat membrane application. The objective was to assess its clinical utility and explore potential therapeutic options in the absence of a definitive reversal agent. All five patients were successfully treated with the "THIS and FAT" protocol, and no major complications were observed. The protocol provides a stepwise therapeutic strategy offering targeted interventions for each stage of ischemia. Managing vascular complications secondary to PCL fillers requires early recognition, rapid implementation of multimodal therapy, and a comprehensive understanding of facial anatomy. In this case series, the "THIS and FAT" protocol guided treatment through a structured, ultrasound-assisted approach that integrates vascular, enzymatic, anti-inflammatory, and regenerative modalities.

PMID 43047175
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Indocyanine Green Angiography for Objective Perfusion Monitoring After Hyaluronic Acid Filler-Induced Facial Vascular Occlusion.

Li Guangdi G, Zhou Guiwen G, Wang Miao M, Ding Hongfan H et al.

Hyaluronic acid (HA) filler-induced facial vascular occlusion may cause cutaneous ischemia, necrosis, and disfigurement. Clinical assessment and imaging-guided hyaluronidase-based intervention remain central, but vessel-level localization does not directly quantify downstream tissue perfusion after rescue treatment. To evaluate indocyanine green angiography (ICGA) as an adjunctive tissue-level tool for monitoring perfusion changes after initial rescue treatment. This exploratory single-center retrospective feasibility study included patients with clinically diagnosed HA filler-induced facial vascular occlusion who underwent paired ICGA before and after initial rescue treatment between July 2025 and March 2026. ICGA-derived parameters included ingress rate, time to peak (TPP), and curve ingress. Curve ingress percent change was calculated as the change in curve ingress divided by baseline curve ingress. Twenty-six patients were included. After initial rescue treatment, median ingress rate increased from 12.50 to 16.20, with a median change of 4.85 (IQR, 3.00-8.57; p < 0.001). Median TPP shortened from 31.46 to 23.87 s, with a median change of -6.09 s (IQR, -11.69 to -3.93; p < 0.001). Median curve ingress increased from 63515.95 to 77862.55, with a median change of 14432.45 (IQR, 9891.28-20269.65; p < 0.001). The two patients requiring treatment escalation showed the lowest percent changes in curve ingress. ICGA demonstrated early tissue-level perfusion changes after initial rescue treatment. Limited early curve ingress improvement may support closer surveillance or timely escalation when interpreted with clinical findings. ClinicalTrials.gov, NCT07581652.

PMID 43047101
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Identification of A Novel Antioxidant Tripeptide Ameliorating Skin Photoaging.

Lu Jianghua J, Li Jie J, Wang Liang L, Xia Liming L et al.

Skin photodamage induced by ultraviolet (UV) exposure is the primary factor of photoaging, and developing bioactive molecules targeting this process represents a key focus in dermatology and cosmetic biotechnology. However, a comprehensive screening strategy combining combinatorial library construction with multi-target validation has not yet been fully established. To establish a systematic screening strategy for bioactive peptide molecules and to assess the antioxidant, anti-photoaging effects of the identified bioactive peptide on skin cells. In this study, 17 out of 20 common amino acids were chosen according to their antioxidant capacity via H2O2- and UVB-induced oxidative stress models. Based on these 17 amino acids, a tripeptide library containing 4913 molecules was constructed using a full combinatorial strategy. With skin melanin synthesis (tyrosinase), extracellular matrix degradation (elastase or hyaluronidase), and oxidative stress regulation (Keap1) as core targets, 10 potential bioactive tripeptides were screened out through molecular docking technology. Subsequently, mitochondrial function was examined by detecting mitochondrial membrane potential and mitochondrial superoxide anion levels to evaluate the antioxidant activity of the identified tripeptide. Detection of mRNA levels of antioxidant-related genes and RNA-seq analysis were performed to investigate the associated signaling pathways. Additionally, senescence-associated β-galactosidase staining was used to assess the anti-aging capacity. In vitro functional validation confirmed that tripeptide FAW exhibited the optimal performance in migration capacity and antioxidant activity for skin cells. Mechanistic studies revealed that FAW may enhance cellular antioxidant capacity by activating the NRF2/HMOX-1 pathway and regulate skin aging-related signaling pathways. The results showed that FAW could alleviated UV-induced skin cell damage and photoaging, and ameliorate passage number-induced replicative senescence. This study established a screening strategy for bioactive peptide molecules, encompassing amino acid screening, tripeptide library construction, multi-target molecular docking, and functional validation. Notably, tripeptide FAW identified in this study showed promising application potential for skincare.

PMID 43046983
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Complications of Hyaluronic Acid and Calcium Hydroxylapatite Fillers-A Comprehensive Narrative Review of Clinical Presentation and Current Management Strategies.

Sukmanskaya Natalia N, Cotofana Sebastian S, Alfertshofer Michael M

Hyaluronic acid (HA) and calcium hydroxylapatite (CaHA) fillers are among the most widely used injectable materials in aesthetic medicine. Although both exhibit favorable safety profiles, concomitant with increasing use comes a broader spectrum of reported complications, ranging from mild, self-limited reactions to rare but potentially dramatic events. To provide a comprehensive narrative review of the clinical presentation and current evidence-based management strategies for common and uncommon complications associated with HA and CaHA fillers. A narrative review of the dermatologic, plastic surgery, ophthalmologic, and aesthetic medicine literature was conducted, focusing on peer-reviewed studies, systematic reviews, expert consensus statements, and illustrative case reports addressing complications of HA and CaHA fillers. Complications were categorized by timing, pathophysiology, and clinical severity, and management approaches were synthesized accordingly. Relevant English-language articles were identified through PubMed/MEDLINE and Scopus up to 2025 using combinations of the different search terms supplemented by hand-searching of reference lists; evidence was weighted qualitatively, giving precedence to consensus statements and larger studies over individual case reports. HA and CaHA fillers share overlapping complication profiles, including bruising, swelling, vascular occlusion, infection, nodules, granulomas, and delayed inflammatory reactions. Key differences arise from their inherent product properties: HA complications benefit from enzymatic reversibility with hyaluronidase, which underpins established treatment algorithms for vascular occlusion, Tyndall effect, chronic edema, and nodules. In contrast, CaHA-related complications rely more heavily on prevention, supportive care, and, in select cases, mechanical removal through surgical intervention, as no enzymatic reversal is available. Early recognition and prompt intervention are critical determinants of outcome, particularly in ischemia-related complications. HA and CaHA fillers are effective and generally safe filler materials, yet not without risk. A thorough understanding of complication patterns, material-specific management strategies, and preventive techniques is essential for clinicians performing filler injections. With appropriate training, education, and safety algorithms to manage adverse events, most complications can be treated effectively, thereby maximizing patient safety and satisfaction.

PMID 43047205
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hyaluronidase